咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Current perspectives and the f... 收藏

Current perspectives and the future of disease-modifying therapies in type 1 diabetes

作     者:Sunetra Mondal Joseph M Pappachan 

作者机构:Department of EndocrinologyNRS Medical College and HospitalKolkata 700014West BengalIndia Department of Endocrinology and MetabolismLancashire Teaching Hospitals NHS TrustPreston PR29HTUnited Kingdom Faculty of ScienceManchester Metropolitan UniversityManchester M156BHUnited Kingdom Department of EndocrinologyKasturba Medical CollegeManipal 576104India 

出 版 物:《World Journal of Diabetes》 (世界糖尿病杂志(英文))

年 卷 期:2025年第16卷第1期

页      面:12-21页

学科分类:1002[医学-临床医学] 100201[医学-内科学(含:心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主  题:Teplizumab Type 1 diabetes mellitus Disease modifying therapy β-cell function C-peptide Immunotherapy 

摘      要:Use of immunomodulating agents to prevent the progression of autoimmuneβ-cell damage leading to type 1 diabetes mellitus(T1DM)is an interesting area for *** include non-specific anti-inflammatory agents,immunologic vaccination and anti-inflammatory agents targeting specific immune cells or *** is an anti-CD3-molecule that binds to and leads to the disappearance of the CD3/TCR complex and rendering the T cell anergic to its target *** and clinical trials have demonstrated its efficacy in reducing the decline in serum C-peptide levels and the need for insulin therapy if used early in the disease process of *** benefits have been apparent as early as six months to as long as seven years after *** has recently been approved by the Food and Drug Administration to delay the onset of clinical(stage 3)type 1 diabetes in children above 8 years of *** their recent metaanalysis published in the World Journal of Diabetes,Ma et al found that those in the teplizumab treatment group have a greater likelihood of reduction in insulin use,change in C-peptide response,and better glycemic control compared to the control group with a good safety ***,all the included randomized control trials have been conducted in high-income *** cost of therapy and unknown utility of the molecule in stage 3 disease limit its widespread use.

读者评论 与其他读者分享你的观点